Preclinical Studies of Valecor Platinum(TM) Coronary Stent System Indicate Positive Results and Improvements Compared to Market-Leading Bare Stent
BURLINGTON, Mass., Oct. 23 /PRNewswire/ -- CorNova, Inc. announced today that S. Eric Ryan, M.D., Chairman & CEO of CorNova, presented preliminary results of its recent preclinical studies for CorNova's Valecor Platinum(TM) Coronary Stent System at the TCT 2007 conference in Washington, D.C. The independently-conducted preclinical studies illustrated what CorNova believes to be meaningful improvements in neointimal proliferation, arterial injury, arterial inflammation, and reendothelialization when compared to a market-leading bare stent in rabbit and porcine models.
Commenting on today's announcement, Dr. Ryan stated, "We are very pleased with the results from these preclinical studies of our Valecor Platinum(TM) Stent, which is designed to maximize biocompatibility while minimizing arterial injury, potentially providing both short and long-term benefits over current bare stent technology. We also believe our Valecor Platinum(TM) Stent may offer the potential of improving coronary stent performance without the need for drug-elution and the inherent risks presented by drug-eluting stents. The Company is proceeding with its efforts to receive CE Mark approval for the Valecor Platinum(TM) Stent and we currently expect to receive that approval in early 2008."
CorNova, Inc., founded in 2003, is a privately-held, development-stage company with an experienced international team of business, medical, and engineering professionals within the field of interventional cardiology. CorNova's business focus is to build value and opportunity through the utilization of the technologies, expertise, and resources of its international team and partner companies to develop and sell innovative endovascular devices. The Company's strategic partners include Implant Sciences Corporation (Amex: IMX) and CardioTech International, Inc. (Amex: CTE).
|SOURCE CorNova, Inc.|
Copyright©2007 PR Newswire.
All rights reserved